| Name | Title | Contact Details |
|---|
Volcano Corporation designs, develops, manufactures and commercializes a suite of intravascular ultrasound (IVUS) and functional measurement (FM) products that seeks to enhance the diagnosis and treatment of vascular and structural heart disease. The
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
Viacor Inc. is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today`s technologies.